文献速递肿瘤 PET/CT核素与放射性配体治疗

18F-FDG PET/CT对接受肽受体放射性核素治疗的晚期转移性神经内分泌肿瘤大样本患者的预后价值

Prognostic Value of 18F-FDG PET/CT in a Large Cohort of Patients with Advanced Metastatic Neuroendocrine Neoplasms Treated with Peptide Receptor Radionuclide Therapy.
PubMed 文献 · J Nucl Med · 2020-03-13

这项回顾性研究纳入495例接受177Lu或90Y-DOTATOC/DOTATATE肽受体放射性核素治疗(PRRT)的转移性神经内分泌肿瘤(NEN)患者,治疗前均行68Ga-SSTR PET/CT与18F-FDG PET/CT并长期随访。18F-FDG PET/CT阳性是PRRT治疗后生存的独立预后因素,与68Ga-SSTR PET/CT联合可补充预后信息;SSTR高表达且18F-FDG阴性者长期预后最佳。

要点

  • 18F-FDG PET/CT阳性患者PRRT后中位无进展生存期18.5个月 vs 阴性24.1个月(P=0.0015)。
  • 18F-FDG PET/CT阳性患者中位总生存期53.2个月 vs 阴性83.1个月(P<0.001)。
  • SSTR高表达且18F-FDG PET/CT阴性者长期预后最佳。

核心结论

  • 18F-FDG PET阳性病灶是接受PRRT治疗的NEN患者独立的预后因素。
  • 18F-FDG PET/CT代谢成像补充68Ga-SSTR PET/CT分子成像用于PRRT后生存预后判断。
  • SSTR高表达合并18F-FDG PET/CT阴性结果与最有利的长期预后相关。

研究设计与样本

  • 回顾性研究纳入495例转移性NEN患者,于2002年2月至2018年7月间接受177Lu-或90Y-DOTATOC/DOTATATE PRRT治疗。
  • 所有患者治疗前均接受68Ga-DOTATOC/TATE/NOC与18F-FDG PET/CT,随访3–189个月。
  • 采用Kaplan-Meier分析、log-rank检验(Mantel-Cox)与Cox回归分析评估总生存期(OS)和无进展生存期(PFS)。

主要发现

  • 199例(40.2%)为胰腺NEN,139例为中肠NEN,49例为原发灶不明,直肠20例、肺38例、胃8例、其他部位42例。
  • PRRT前18F-FDG PET/CT阳性382例(77.2%)、阴性113例(22.8%),而68Ga-DOTATOC/TATE/NOC阳性率为100%。
  • 全部患者自PRRT开始的中位PFS为19.6个月、中位OS为58.7个月。
  • 18F-FDG阳性者较阴性者PFS更短(18.5个月 vs 24.1个月,P=0.0015)、OS更短(53.2个月 vs 83.1个月,P<0.001)。
  • 胰腺NEN中18F-FDG阳性者中位OS为52.8个月 vs 阴性者114.3个月(P=0.0006)。

关键数值与推荐

  • 全部18F-FDG阳性患者中,68Ga-SSTR PET最高SUVmax与最18F-FDG高摄取病灶比值大于2者中位OS为53.0个月,比值小于2者为43.4个月(P=0.030)。
  • 18F-FDG无摄取(完全不匹配成像模式)患者中,68Ga-SSTR PET/CT SUVmax大于15.0者中位OS为108.3个月 vs SUVmax≤15.0者76.9个月。

临床怎么用

  • 原文结论未据此给出推荐。
  • 原文指出18F-FDG PET/CT代谢成像补充68Ga-SSTR PET/CT分子成像用于PRRT后生存预后判断。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The objective of this retrospective study was to determine the role of 18F-FDG PET/CT in a large cohort of 495 patients with metastatic neuroendocrine neoplasms (NENs) who were treated with peptide receptor radionuclide therapy (PRRT) with a long-term follow-up. Methods: The 495 patients were treated with 177Lu- or 90Y-DOTATOC/DOTATATE PRRT between February 2002 and July 2018. All subjects received both 68Ga-DOTATOC/TATE/NOC and 18F-FDG PET/CT before treatment and were followed 3-189 mo. Kaplan-Meier analysis, log-rank testing (Mantel-Cox), and Cox regression analysis were performed for overall survival (OS) and progression-free survival (PFS). Results: One hundred ninety-nine patients (40.2%) presented with pancreatic NENs, 49 with cancer of unknown primary, and 139 with midgut NENs, whereas the primary tumor was present in the rectum in 20, in the lung in 38, in the stomach in 8, and in other locations in 42. 18F-FDG PET/CT was positive in 382 (77.2%) patients and negative in 113 (22.8%) before PRRT, whereas 100% were 68Ga-DOTATOC/TATE/NOC-positive. For all patients, the median PFS and OS, defined from the start of PRRT, were 19.6 mo and 58.7 mo, respectively. Positive 18F-FDG results predicted shorter PFS (18.5 mo vs. 24.1 mo; P = 0.0015) and OS (53.2 mo vs. 83.1 mo; P < 0.001) than negative 18F-FDG results. Among the cases of pancreatic NENs, the median OS was 52.8 mo in 18F-FDG-positive subjects and 114.3 mo in 18F-FDG-negative subjects (P = 0.0006). For all patients positive for 18F-FDG uptake, and a ratio of more than 2 for the highest SUVmax on 68Ga-somatostatin receptor (SSTR) PET to the most 18F-FDG-avid tumor lesions, the median OS was 53.0 mo, compared with 43.4 mo in those patients with a ratio of less than 2 (P = 0.030). For patients with no 18F-FDG uptake (complete mismatch imaging pattern), the median OS was 108.3 mo versus 76.9 mo for an SUVmax of more than 15.0 and an SUVmax of 15.0 or less on 68Ga-SSTR PET/CT, respectively. Conclusion: The presence of positive lesions on 18F-FDG PET is an independent prognostic factor in patients with NENs treated with PRRT. Metabolic imaging with 18F-FDG PET/CT complements the molecular imaging aspect of 68Ga-SSTR PET/CT for the prognosis of survival after PRRT. High SSTR expression combined with negative 18F-FDG PET/CT results is associated with the most favorable long-term prognosis.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Zhang J, Liu Q, Singh A, et al. Prognostic Value of 18F-FDG PET/CT in a Large Cohort of Patients with Advanced Metastatic Neuroendocrine Neoplasms Treated with Peptide Receptor Radionuclide Therapy. J Nucl Med. 2020. PMID: 32169914. doi:10.2967/jnumed.119.241414

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。